

## Bora Pharmaceuticals Reports Consolidated Revenue of NT\$2.30 Billion in June

### 保瑞公告 6 月自結合併營收新台幣 23 億 0 仟萬元

Taipei, Taiwan, July 8, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for June 2026 reached another historical high of NT\$2.30 billion, an increase of 8.67% against May. June revenues grew 39.22% year-over-year. Cumulative revenue decline for the year has narrowed to 1.14%, and we expect year-over-year growth to turn positive in the second half.

台北，台灣，2026 年 7 月 8 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 6 月自結合併營收為新台幣 23 億 0 仟萬元，較 5 月再增 8.67%；6 月營收較去年同期大幅增長 39.22%，今年累計營收衰退收斂至 1.14%，預期下半年即可翻正進入年增。

The record-high revenue was driven primarily by Upsher-Smith's return to its growth trajectory in pharma sales, alongside steady CDMO performance. With the Rockville biologics drug substance CDMO facility to be consolidated from July, Bora Group is poised to achieve a more diversified and resilient revenue mix in 2026, underscoring the value of our end-to-end CDMO solutions and reducing reliance on any single flagship product.

營收再創新猷主要來自全球銷售業務 Upsher-Smith 重拾成長曲線且 CDMO 業績持穩，展望 7 月即將併表生物製劑 CDMO 廠區 Rockville 廠，保瑞集團的營收組成將於 2026 年更加多元而穩固，彰顯單一團隊、整合式 CDMO 解決方案的價值，降低對旗艦型產品的依賴。

Bora will attend BIO Asia–Taiwan 2026, taking place July 14–19, where the Company will host facility tours, small-group sessions, and one-on-one meetings with potential clients and investors

保瑞集團將於 7 月 14 日至 19 日參加 2026 BIO Asia Taiwan 展會，與潛在客戶及投資人進行訪廠、小型及面對面會議。

#### About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

**Investor/Media enquiries 新聞聯繫人：**

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)